Compare IAC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IAC | SYRE |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1992 | 2016 |
| Metric | IAC | SYRE |
|---|---|---|
| Price | $39.50 | $32.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $45.91 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 759.3K | 598.5K |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,653,760,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.49 | N/A |
| 52 Week Low | $29.56 | $10.91 |
| 52 Week High | $50.49 | $35.31 |
| Indicator | IAC | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 50.75 |
| Support Level | $38.39 | $31.62 |
| Resistance Level | $40.52 | $35.07 |
| Average True Range (ATR) | 1.02 | 1.88 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 53.66 | 59.45 |
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.